Study Phase 2

A 9 Month, Double-Blind, Placebo-Controlled Study With a Blinded Crossover Transition to Open-Label Extension, Evaluating the Safety and Effectiveness of Topiramate on Insulin Sensitivity in Overweight or Obese Type 2 Diabetes Patients

Trial Information

Generic NameTopiramateProduct NameTOPAMAX®Therapeutic AreaNutritional and Metabolic DiseasesEnrollment38% FemaleN/A% WhiteN/A
Product ClassAnticonvulsantsSponsor Protocol NumberTOPMAT-OBDM-001Data PartnerJohnson & JohnsonCondition StudiedObesityMean/Median Age (Years)N/A

Supporting Documentation

  • Collected Datasets Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.